Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Contributed by: PR Newswire

Tags

Lundbeck

More Like This

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

BioArctic receives Orphan Drug Designation for exidavnemab the US

Exidavnemab phase 2a study expanded to include MSA patients

PR Newswire associated0

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

PR Newswire associated0

AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy

Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain

Eisai will request reconsideration of initial decision for lecanemab in Australia

Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025